Financhill
Buy
51

HALO Quote, Financials, Valuation and Earnings

Last price:
$46.72
Seasonality move :
7.09%
Day range:
$46.88 - $48.21
52-week range:
$33.15 - $65.53
Dividend yield:
0%
P/E ratio:
15.54x
P/S ratio:
6.43x
P/B ratio:
13.19x
Volume:
4.5M
Avg. volume:
2M
1-year change:
29%
Market cap:
$6B
Revenue:
$829.3M
EPS (TTM):
$3.02

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
HALO
Halozyme Therapeutics
$252.2M $1.00 26.98% 85.37% $64.13
KURA
Kura Oncology
-- -$0.61 -- -21.73% --
LUNG
Pulmonx
$20.3M -$0.44 15.63% -24.71% --
LXRX
Lexicon Pharmaceuticals
$2.9M -$0.17 910.29% -37.45% $3.60
NVAX
Novavax
$73.8M -$0.75 -64.12% -56.12% $16.00
TMDX
TransMedics Group
$115M $0.32 36.1% 28.58% $102.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
HALO
Halozyme Therapeutics
$46.93 $64.13 $6B 15.54x $0.00 0% 6.43x
KURA
Kura Oncology
$9.01 -- $700.7M -- $0.00 0% --
LUNG
Pulmonx
$6.16 -- $243.2M -- $0.00 0% 3.01x
LXRX
Lexicon Pharmaceuticals
$0.71 $3.60 $258.4M -- $0.00 0% 39.74x
NVAX
Novavax
$8.72 $16.00 $1.4B -- $0.00 0% 1.52x
TMDX
TransMedics Group
$61.74 $102.00 $2.1B 65.68x $0.00 0% 5.32x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
HALO
Halozyme Therapeutics
76.87% 1.923 20.66% 8.75x
KURA
Kura Oncology
-- 0.921 -- --
LUNG
Pulmonx
28.39% 1.298 11.37% 6.56x
LXRX
Lexicon Pharmaceuticals
35.88% 1.185 17.6% 7.25x
NVAX
Novavax
-47.39% 8.483 8.37% 0.85x
TMDX
TransMedics Group
70.78% 1.280 9.65% 7.00x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
HALO
Halozyme Therapeutics
$240.7M $163.2M 22.41% 156.62% 58.49% $113.9M
KURA
Kura Oncology
-- -$59.9M -- -- -- -$43.4M
LUNG
Pulmonx
$15M -$14.1M -38.81% -51.95% -64.07% -$7.7M
LXRX
Lexicon Pharmaceuticals
$1.7M -$63.7M -75.24% -115.11% -3442.8% -$53.9M
NVAX
Novavax
$23.9M -$134M -- -- -139.74% -$146.8M
TMDX
TransMedics Group
$60.8M $3.9M 4.86% 19.83% 7.23% -$41.3M

Halozyme Therapeutics vs. Competitors

  • Which has Higher Returns HALO or KURA?

    Kura Oncology has a net margin of 47.23% compared to Halozyme Therapeutics's net margin of --. Halozyme Therapeutics's return on equity of 156.62% beat Kura Oncology's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    HALO
    Halozyme Therapeutics
    82.96% $1.05 $2B
    KURA
    Kura Oncology
    -- -$0.63 --
  • What do Analysts Say About HALO or KURA?

    Halozyme Therapeutics has a consensus price target of $64.13, signalling upside risk potential of 36.64%. On the other hand Kura Oncology has an analysts' consensus of -- which suggests that it could grow by 217.11%. Given that Kura Oncology has higher upside potential than Halozyme Therapeutics, analysts believe Kura Oncology is more attractive than Halozyme Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    HALO
    Halozyme Therapeutics
    3 4 0
    KURA
    Kura Oncology
    0 0 0
  • Is HALO or KURA More Risky?

    Halozyme Therapeutics has a beta of 1.226, which suggesting that the stock is 22.555% more volatile than S&P 500. In comparison Kura Oncology has a beta of 0.746, suggesting its less volatile than the S&P 500 by 25.385%.

  • Which is a Better Dividend Stock HALO or KURA?

    Halozyme Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kura Oncology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Halozyme Therapeutics pays -- of its earnings as a dividend. Kura Oncology pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios HALO or KURA?

    Halozyme Therapeutics quarterly revenues are $290.1M, which are larger than Kura Oncology quarterly revenues of --. Halozyme Therapeutics's net income of $137M is higher than Kura Oncology's net income of -$54.4M. Notably, Halozyme Therapeutics's price-to-earnings ratio is 15.54x while Kura Oncology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Halozyme Therapeutics is 6.43x versus -- for Kura Oncology. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HALO
    Halozyme Therapeutics
    6.43x 15.54x $290.1M $137M
    KURA
    Kura Oncology
    -- -- -- -$54.4M
  • Which has Higher Returns HALO or LUNG?

    Pulmonx has a net margin of 47.23% compared to Halozyme Therapeutics's net margin of -69.38%. Halozyme Therapeutics's return on equity of 156.62% beat Pulmonx's return on equity of -51.95%.

    Company Gross Margin Earnings Per Share Invested Capital
    HALO
    Halozyme Therapeutics
    82.96% $1.05 $2B
    LUNG
    Pulmonx
    73.7% -$0.36 $131.2M
  • What do Analysts Say About HALO or LUNG?

    Halozyme Therapeutics has a consensus price target of $64.13, signalling upside risk potential of 36.64%. On the other hand Pulmonx has an analysts' consensus of -- which suggests that it could grow by 93.45%. Given that Pulmonx has higher upside potential than Halozyme Therapeutics, analysts believe Pulmonx is more attractive than Halozyme Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    HALO
    Halozyme Therapeutics
    3 4 0
    LUNG
    Pulmonx
    0 0 0
  • Is HALO or LUNG More Risky?

    Halozyme Therapeutics has a beta of 1.226, which suggesting that the stock is 22.555% more volatile than S&P 500. In comparison Pulmonx has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock HALO or LUNG?

    Halozyme Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pulmonx offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Halozyme Therapeutics pays -- of its earnings as a dividend. Pulmonx pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios HALO or LUNG?

    Halozyme Therapeutics quarterly revenues are $290.1M, which are larger than Pulmonx quarterly revenues of $20.4M. Halozyme Therapeutics's net income of $137M is higher than Pulmonx's net income of -$14.1M. Notably, Halozyme Therapeutics's price-to-earnings ratio is 15.54x while Pulmonx's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Halozyme Therapeutics is 6.43x versus 3.01x for Pulmonx. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HALO
    Halozyme Therapeutics
    6.43x 15.54x $290.1M $137M
    LUNG
    Pulmonx
    3.01x -- $20.4M -$14.1M
  • Which has Higher Returns HALO or LXRX?

    Lexicon Pharmaceuticals has a net margin of 47.23% compared to Halozyme Therapeutics's net margin of -3703.49%. Halozyme Therapeutics's return on equity of 156.62% beat Lexicon Pharmaceuticals's return on equity of -115.11%.

    Company Gross Margin Earnings Per Share Invested Capital
    HALO
    Halozyme Therapeutics
    82.96% $1.05 $2B
    LXRX
    Lexicon Pharmaceuticals
    95.94% -$0.18 $278.4M
  • What do Analysts Say About HALO or LXRX?

    Halozyme Therapeutics has a consensus price target of $64.13, signalling upside risk potential of 36.64%. On the other hand Lexicon Pharmaceuticals has an analysts' consensus of $3.60 which suggests that it could grow by 403.71%. Given that Lexicon Pharmaceuticals has higher upside potential than Halozyme Therapeutics, analysts believe Lexicon Pharmaceuticals is more attractive than Halozyme Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    HALO
    Halozyme Therapeutics
    3 4 0
    LXRX
    Lexicon Pharmaceuticals
    2 2 0
  • Is HALO or LXRX More Risky?

    Halozyme Therapeutics has a beta of 1.226, which suggesting that the stock is 22.555% more volatile than S&P 500. In comparison Lexicon Pharmaceuticals has a beta of 1.069, suggesting its more volatile than the S&P 500 by 6.862%.

  • Which is a Better Dividend Stock HALO or LXRX?

    Halozyme Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexicon Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Halozyme Therapeutics pays -- of its earnings as a dividend. Lexicon Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios HALO or LXRX?

    Halozyme Therapeutics quarterly revenues are $290.1M, which are larger than Lexicon Pharmaceuticals quarterly revenues of $1.8M. Halozyme Therapeutics's net income of $137M is higher than Lexicon Pharmaceuticals's net income of -$64.8M. Notably, Halozyme Therapeutics's price-to-earnings ratio is 15.54x while Lexicon Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Halozyme Therapeutics is 6.43x versus 39.74x for Lexicon Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HALO
    Halozyme Therapeutics
    6.43x 15.54x $290.1M $137M
    LXRX
    Lexicon Pharmaceuticals
    39.74x -- $1.8M -$64.8M
  • Which has Higher Returns HALO or NVAX?

    Novavax has a net margin of 47.23% compared to Halozyme Therapeutics's net margin of -143.53%. Halozyme Therapeutics's return on equity of 156.62% beat Novavax's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    HALO
    Halozyme Therapeutics
    82.96% $1.05 $2B
    NVAX
    Novavax
    28.27% -$0.76 -$357.2M
  • What do Analysts Say About HALO or NVAX?

    Halozyme Therapeutics has a consensus price target of $64.13, signalling upside risk potential of 36.64%. On the other hand Novavax has an analysts' consensus of $16.00 which suggests that it could grow by 83.59%. Given that Novavax has higher upside potential than Halozyme Therapeutics, analysts believe Novavax is more attractive than Halozyme Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    HALO
    Halozyme Therapeutics
    3 4 0
    NVAX
    Novavax
    2 2 0
  • Is HALO or NVAX More Risky?

    Halozyme Therapeutics has a beta of 1.226, which suggesting that the stock is 22.555% more volatile than S&P 500. In comparison Novavax has a beta of 2.017, suggesting its more volatile than the S&P 500 by 101.749%.

  • Which is a Better Dividend Stock HALO or NVAX?

    Halozyme Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novavax offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Halozyme Therapeutics pays -- of its earnings as a dividend. Novavax pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios HALO or NVAX?

    Halozyme Therapeutics quarterly revenues are $290.1M, which are larger than Novavax quarterly revenues of $84.5M. Halozyme Therapeutics's net income of $137M is higher than Novavax's net income of -$121.3M. Notably, Halozyme Therapeutics's price-to-earnings ratio is 15.54x while Novavax's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Halozyme Therapeutics is 6.43x versus 1.52x for Novavax. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HALO
    Halozyme Therapeutics
    6.43x 15.54x $290.1M $137M
    NVAX
    Novavax
    1.52x -- $84.5M -$121.3M
  • Which has Higher Returns HALO or TMDX?

    TransMedics Group has a net margin of 47.23% compared to Halozyme Therapeutics's net margin of 3.88%. Halozyme Therapeutics's return on equity of 156.62% beat TransMedics Group's return on equity of 19.83%.

    Company Gross Margin Earnings Per Share Invested Capital
    HALO
    Halozyme Therapeutics
    82.96% $1.05 $2B
    TMDX
    TransMedics Group
    55.94% $0.12 $718.5M
  • What do Analysts Say About HALO or TMDX?

    Halozyme Therapeutics has a consensus price target of $64.13, signalling upside risk potential of 36.64%. On the other hand TransMedics Group has an analysts' consensus of $102.00 which suggests that it could grow by 65.21%. Given that TransMedics Group has higher upside potential than Halozyme Therapeutics, analysts believe TransMedics Group is more attractive than Halozyme Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    HALO
    Halozyme Therapeutics
    3 4 0
    TMDX
    TransMedics Group
    5 3 0
  • Is HALO or TMDX More Risky?

    Halozyme Therapeutics has a beta of 1.226, which suggesting that the stock is 22.555% more volatile than S&P 500. In comparison TransMedics Group has a beta of 2.058, suggesting its more volatile than the S&P 500 by 105.81%.

  • Which is a Better Dividend Stock HALO or TMDX?

    Halozyme Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TransMedics Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Halozyme Therapeutics pays -- of its earnings as a dividend. TransMedics Group pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios HALO or TMDX?

    Halozyme Therapeutics quarterly revenues are $290.1M, which are larger than TransMedics Group quarterly revenues of $108.8M. Halozyme Therapeutics's net income of $137M is higher than TransMedics Group's net income of $4.2M. Notably, Halozyme Therapeutics's price-to-earnings ratio is 15.54x while TransMedics Group's PE ratio is 65.68x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Halozyme Therapeutics is 6.43x versus 5.32x for TransMedics Group. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HALO
    Halozyme Therapeutics
    6.43x 15.54x $290.1M $137M
    TMDX
    TransMedics Group
    5.32x 65.68x $108.8M $4.2M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret

It’s not often that a company with the scale and…

Will Tyson Foods Stock Bounce Back?
Will Tyson Foods Stock Bounce Back?

Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…

Will Iovance Biotherapeutics Stock Bounce Back?
Will Iovance Biotherapeutics Stock Bounce Back?

Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…

Stock Ideas

Buy
64
Is AAPL Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 42x

Buy
52
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 113x

Buy
55
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 37x

Alerts

Buy
61
QMCO alert for Dec 23

Quantum [QMCO] is up 0.73% over the past day.

Sell
46
NUKK alert for Dec 23

Nukkleus [NUKK] is up 6.88% over the past day.

Sell
1
IIPR alert for Dec 23

Innovative Industrial Properties [IIPR] is down 5.35% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock